Type 1 Diabetes: Competitive Landscape to 2026

Table of Contents
1. Preface 2
1.1 Table of Contents 2
1.2 Abbreviations 3
1.3 Related Reports 4
1.4 Upcoming Related Reports 5
2. Executive Summary 6
2.2 Key Findings 7
2.2 Key Events 8
3. Introduction 9
3.1 Report Scope 10
3.2 Disease Overview and Epidemiology 12
4. Pipeline Assessment 14
4.1 Pipeline Overview 15
4.2 Pipeline Breakdown by Region/Country 17
4.3 Pipeline Breakdown by Molecule Type and Target 18
4.4 Drug Review Designations 19
4.5 Products in Clinical Development 20
5. Clinical Trial Assessment 22
5.1 Clinical Trials Overview 23
5.2 Top Sponsors of Clinical Trials in T1D 24
5.3 Trial Breakdown by Region 26
5.4 Therapy Area Perspective 27
5.5 Enrollment Analytics 28
6 Commercial Assessment 31
6.1 LeadingMarketed Products 32
6.2 Current & Future Players 33
7. Competitive Landscape Analysis (2016-2026) 34
7.1 Events Classification Overview 35
7.2 US 36
7.3 5EU 37
7.4 Japan and China 38
8 Appendix 39
8.1 Sources 40
8.2 Methodology 41
8.3 Key Events Included in the Analysis 42
8.4 About the Authors 43
8.5 About GlobalData 46
8.6 Disclaimer 48